Govindan R, et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12Cinhibitor, evaluated in NSCLC. Abstract OA02.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Dabrafenib plus trametinib bij BRAF-V600E-gemuteerde zeldzame tumoren
jun 2023 | Hoofd-halsoncologie, Leukemie, Maag-darm-leveroncologie, MM, Neuro-oncologie